Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AnaptysBio, Inc. (ANAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on immunology therapeutics, AnaptysBio uses these filings to report material events related to its clinical programs, collaborations, capital allocation decisions and strategic plans.
Recent Form 8-K filings describe several categories of information. Some filings report results of operations and financial condition, where AnaptysBio furnishes press releases detailing quarterly financial results and business updates. Others fall under Regulation FD disclosure, such as filings that provide updated corporate investor presentations or slide decks used in conference calls discussing programs like ANB033 or the company’s broader pipeline.
Additional 8-Ks highlight other events, including board authorization of amendments to the company’s stock repurchase plan and the board’s approval of plans to explore separating AnaptysBio’s business into two independent, publicly traded companies by the end of 2026. Filings also cover the company’s Verified Complaint in Delaware Chancery Court against Tesaro and GSK concerning the Collaboration and Exclusive License Agreement for Jemperli, as well as references to Tesaro and GSK’s complaint against AnaptysBio.
For investors analyzing ANAB, these filings help clarify how AnaptysBio reports litigation developments, collaboration terms, royalty monetization arrangements, and major strategic decisions. On Stock Titan, SEC documents are paired with AI-powered summaries that explain the main points of each filing in plain language, highlight notable items such as litigation updates or changes to repurchase plans, and make it easier to scan multiple 8-Ks and other forms without reading every line of legal text.
AnaptysBio director Dennis M. Fenton reported new equity awards. On January 6, 2026, he received a stock option for 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share, held directly. The option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, conditioned on continued service.
On the same date, he was also granted 4,000 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock for no cash consideration. These RSUs vest in full on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service to the company.
AnaptysBio director Rita Jain reported new equity awards. On January 6, 2026, she received a stock option covering 5,500 shares of AnaptysBio common stock with an exercise price of $43.91 per share. According to the disclosure, this option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, so long as she continues to provide services to the company.
The filing also shows a grant of 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs are scheduled to vest 100% on the date of AnaptysBio’s 2027 annual meeting of shareholders, again conditioned on continued service. After these awards, Jain beneficially owns 5,500 stock options and 4,000 RSUs directly.
AnaptysBio director Magda Marquet reported new equity awards from the company. On January 6, 2026, she received a stock option to buy 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share. This option vests in equal 1/12 installments each month starting on February 6, 2026, as long as she continues providing service to the company on each vesting date.
On the same date, she was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs vest as to 100% of the total award on the date of AnaptysBio’s 2027 annual meeting of shareholders, contingent on her continued service through that date.
AnaptysBio, Inc. director Renton Hollings received new equity awards on January 6, 2026. He was granted a stock option for 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share, with no purchase price for the grant itself. This option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, so long as he continues to provide service on each vesting date.
He was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs vest as to 100% of the 4,000 units on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service through that date.
AnaptysBio, Inc. reported a Form 4 for director John P. SchmidJanuary 6, 2026, he received a stock option covering 5,500 shares of common stock with an exercise price of $43.91 per share. This option vests in equal monthly installments of 1/12 starting February 6, 2026, so long as he continues providing service to the company.
Schmid was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of AnaptysBio common stock for no cash payment. These RSUs vest 100% on the date of the company’s 2027 annual meeting of shareholders, contingent on his continued service through that date.
AnaptysBio, Inc. granted equity awards to director Ware J. Anthony. On 01/06/2026, he received a stock option for 5,500 shares of common stock with a $43.91 exercise price and no upfront cost. The option vests in 12 equal monthly installments of 1/12 each, starting on February 6, 2026, as long as he continues providing service to the company on each vesting date.
On the same date, he was also granted 4,000 restricted stock units. Each RSU represents a right to receive one share of AnaptysBio common stock for no consideration. All 4,000 RSUs are scheduled to vest in full on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service through that date.
AnaptysBio, Inc. director John A. Orwin reported new equity awards on a Form 4. On January 6, 2026, he was granted a stock option covering 8,250 shares of common stock with an exercise price of $43.91 per share. This option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, as long as he continues providing service to the company on each vesting date.
On the same date, he also received 6,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration. These RSUs vest as to 100% of the total units on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service. Both the option and RSUs are reported as held directly.
Eric J. Loumeau filed a Form 144 notice covering a planned sale of 7,622 shares of ANAB common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $348,212.59. The shares are part of restricted stock awards acquired on January 3, 2025 (4,294 shares) and January 6, 2025 (3,328 shares), both from the issuer.
Over the prior three months, the notice lists multiple sales of ANAB common stock by Loumeau, including 10,000 shares sold on December 17, 2025 for $460,000.00, another 10,000 shares on December 22, 2025 for $510,000.00, and 12,500 shares on December 16, 2025 for $560,800.25, plus smaller transactions. The form also includes a representation that the seller does not know of undisclosed material adverse information about ANAB.
AnaptysBio, Inc. President and CEO Daniel Faga reported equity transactions in a Form 4. On January 3, 2026, 34,677 restricted stock units (RSUs) were converted into the same number of shares of common stock at an exercise price of $0, reflecting RSU vesting. Each RSU represents a right to receive 1 share of common stock upon settlement for no consideration.
On January 5, 2026, Faga sold 15,309 shares of common stock at $43.26 per share. According to the footnote, this sale was made solely to cover tax withholding obligations through a “sell to cover” transaction and did not represent a discretionary sale. After these transactions, Faga directly beneficially owned 458,139 shares of common stock and 69,355 RSUs.
AnaptysBio, Inc. chief financial officer Dennis Mulroy reported the vesting of 8,292 restricted stock units on January 3, 2026, which converted into the same number of common shares at no cost upon settlement. Following this, his directly held common stock position increased to 17,693 shares.
On January 5, 2026, he sold 3,363 shares of AnaptysBio common stock at a price of $43.26 per share to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary “sell to cover” transaction. After the sale, he directly held 14,330 shares of common stock and 16,585 RSUs, which continue to vest in 25% annual installments beginning January 3, 2025, subject to continued service.
FAQ
What is the current stock price of Anaptysbio (ANAB)?
What is the market cap of Anaptysbio (ANAB)?
